Biosimilar cost savings yet to materialise, says healthcare organisation

26-08-2016

Biosimilar cost savings yet to materialise, says healthcare organisation

Makistock / shutterstock.com

Although the biosimilar market in the US is still early in development, US payers believe that the expected cost savings offered by biosimilar products have yet to materialise.


RG+A, biosimilar, competition

LSIPR